Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07098806 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
A Phase 1 study of Leptomeningeal Metastasis, sponsored by Plus Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07098806: Recruiting Phase 1 study of Leptomeningeal Metastasis, sponsored by Plus Therapeutics.
NCT07098806 is a Phase 1 study of Leptomeningeal Metastasis that is actively recruiting participants, run by Plus Therapeutics. The registered enrollment target is 24 participants, below the 57-participant average among 6 other Leptomeningeal Metastasis trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07098806, a Phase 1 study of Leptomeningeal Metastasis, is actively recruiting participants, sponsored by Plus Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.
Primary Outcome
Evaluation of any toxicity associated with research treatment per Common Criteria for Adverse Events.
Conditions Studied
Interventions
- DRUG 186RNL
Study Locations (1)
Texas
- The Cancer Therapy and Research Center at UTHSCSA - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2031-10-02 |
| Phase | Phase 1 |
What NCT07098806 shows while recruiting
NCT07098806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 57-participant average among 6 other Leptomeningeal Metastasis trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Leptomeningeal Metastasis appearing as the primary indexed condition, and to 1 intervention - of which 186RNL is the first listed.
NCT07098806 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07098806 about?
NCT07098806 is a clinical study titled "Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases". This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases ...
What is the current status of trial NCT07098806?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-07-02. Estimated completion is 2031-10-02.
What conditions does trial NCT07098806 study?
This clinical trial studies the following conditions: Leptomeningeal Metastasis.
What interventions are being tested in trial NCT07098806?
The interventions under investigation include: 186RNL (DRUG).
Who is sponsoring clinical trial NCT07098806?
This trial is sponsored by Plus Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07098806 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leptomeningeal Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
RECRUITING · Phase 1
-
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
-
GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
-
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RECRUITING · Phase 2
-
Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI